PL357490A1 - Sposób wytwarzania bezpostaciowej soli wapniowej aSposób wytwarzania bezpostaciowej soli wapniowej atorwastatynytorwastatyny - Google Patents

Sposób wytwarzania bezpostaciowej soli wapniowej aSposób wytwarzania bezpostaciowej soli wapniowej atorwastatynytorwastatyny

Info

Publication number
PL357490A1
PL357490A1 PL02357490A PL35749002A PL357490A1 PL 357490 A1 PL357490 A1 PL 357490A1 PL 02357490 A PL02357490 A PL 02357490A PL 35749002 A PL35749002 A PL 35749002A PL 357490 A1 PL357490 A1 PL 357490A1
Authority
PL
Poland
Prior art keywords
calcium salt
obtaining amorphous
atorvastatine
atorvastatine calcium
amorphous
Prior art date
Application number
PL02357490A
Other languages
English (en)
Inventor
Virendra KumarAgarwal Virendra Kumar Agarwal
Manish HarshadbhaiVakil Manish Harshadbhai Vakil
KanwalPandita Kanwal Pandita
Satish ChampaklalManakiwala Satish Champaklal Manakiwala
Pankaj RamanbhaiPatel Pankaj Ramanbhai Patel
Original Assignee
Cadila Healthcare Limitedcadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limitedcadila Healthcare Limited filed Critical Cadila Healthcare Limitedcadila Healthcare Limited
Publication of PL357490A1 publication Critical patent/PL357490A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL02357490A 2002-05-28 2002-12-02 Sposób wytwarzania bezpostaciowej soli wapniowej aSposób wytwarzania bezpostaciowej soli wapniowej atorwastatynytorwastatyny PL357490A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN472MU2002 2002-05-28

Publications (1)

Publication Number Publication Date
PL357490A1 true PL357490A1 (pl) 2003-12-01

Family

ID=29560492

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02357490A PL357490A1 (pl) 2002-05-28 2002-12-02 Sposób wytwarzania bezpostaciowej soli wapniowej aSposób wytwarzania bezpostaciowej soli wapniowej atorwastatynytorwastatyny

Country Status (3)

Country Link
AU (1) AU2002356423A1 (pl)
PL (1) PL357490A1 (pl)
WO (1) WO2003099785A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2666359A1 (en) 2004-03-17 2005-10-06 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
EP1711464A2 (en) * 2004-07-22 2006-10-18 Teva Pharmaceutical Industries Ltd Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006021969A1 (en) * 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
CA2582087A1 (en) * 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (pl) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms

Also Published As

Publication number Publication date
WO2003099785A1 (en) 2003-12-04
AU2002356423A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
IL166626A0 (en) Process for preparing the calcium salt of rosuvastatin
AU2003291352A8 (en) Method of securing vertebrae
IL173858A0 (en) Process for preparation of rosuvastatin calcium
GB0325192D0 (en) Method of use
PL370481A1 (pl) Sole walsartanu
EP1577280A4 (en) DEUTERATION PROCESS
PL367278A1 (pl) Sposób zapobiegania tworzeniu kamienia soli wapniowej
PL367302A1 (pl) Sposób zapobiegania tworzeniu kamienia soli wapniowej
AU2002367010A1 (en) Method of purifying brine
AU2003234223A8 (en) Method of endovascular brain mapping
GB0217736D0 (en) Method of controlling scale formation
IL166600A0 (en) Method of treating osteoarthritis
HUP0300761A3 (en) Process for the production of amorphous atorvastatin calcium
PL357490A1 (pl) Sposób wytwarzania bezpostaciowej soli wapniowej aSposób wytwarzania bezpostaciowej soli wapniowej atorwastatynytorwastatyny
EP1488046A4 (en) CONSTRUCTION METHODS
AU2002258036A8 (en) A method of making salt
PL359519A1 (pl) Sposób wytwarzania soli diketonów bicyklicznych
PL359520A1 (pl) Sposób wytwarzania cyklicznych diketonów
GB0220125D0 (en) Method of forming pocketted sponges
PL355939A1 (pl) Ulepszony sposób prowadzenia procesu krystalizacji soli cefuroksymu
PL353465A1 (pl) Sposób wytwarzania soli półwapniowej atorwastatyny w zasadniczo amorficznej postaci
AU2003272327A8 (en) Methods of bone healing
PL351603A1 (en) Method of obtaining a modified chitozane salt gel
GB0213198D0 (en) Method of treatment
AU2003262803A8 (en) Method of obtaining amorphous solid particles

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)